Loading
A phase 1 trial of OPB-201 run by Outpace Bio, Inc., now recruiting.
A Phase 1 Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer. is a phase 1 interventional study registered as NCT07664735 by Outpace Bio, Inc., with 30 participants planned, started 2026-06-30. Conditions recorded: Endometrial Cancer Recurrent, Endometrial Cancer, Advanced Endometrial Cancer, Ovarian Cancer, Ovarian Cancer Recurrent, Platinum Resistant Ovarian Cancer and Endometrial Cancers. Interventions recorded: OPB-201.
Shares Outpace Bio, Platinum-resistant ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Platinum-resistant ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Outpace Bio, Platinum-resistant ovarian cancer and the tag pipeline.
Shares Outpace Bio and the tag pipeline.
Shares Platinum-resistant ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Platinum-resistant ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer and the tag pipeline.
Shares Platinum-resistant ovarian cancer, Ovarian cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/